US11796443B2 - Method for isolating placental trophoblast cells from cervical exfoliated cells of pregnant woman - Google Patents

Method for isolating placental trophoblast cells from cervical exfoliated cells of pregnant woman Download PDF

Info

Publication number
US11796443B2
US11796443B2 US18/009,740 US202218009740A US11796443B2 US 11796443 B2 US11796443 B2 US 11796443B2 US 202218009740 A US202218009740 A US 202218009740A US 11796443 B2 US11796443 B2 US 11796443B2
Authority
US
United States
Prior art keywords
hla
cells
sorting
outlet
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US18/009,740
Other languages
English (en)
Other versions
US20230228667A1 (en
Inventor
Yan Zheng
Jiayan MA
Xiaowei FENG
Mengyu LIU
Peixuan CHEN
Zhisheng GUAN
Longxu XIE
Yiyuan GE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGDONG HYBRIBIO BIOTECH Co Ltd
Guangzhou Hybribio Medicine Technology Ltd
Original Assignee
GUANGDONG HYBRIBIO BIOTECH Co Ltd
Guangzhou Hybribio Medicine Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGDONG HYBRIBIO BIOTECH Co Ltd, Guangzhou Hybribio Medicine Technology Ltd filed Critical GUANGDONG HYBRIBIO BIOTECH Co Ltd
Assigned to GUANGDONG HYBRIBIO BIOTECH CO., LTD., GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD. reassignment GUANGDONG HYBRIBIO BIOTECH CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, Peixuan, FENG, XIAOWEI, GE, Yiyuan, GUAN, ZHISHENG, LIU, Mengyu, MA, Jiayan, XIE, LONGXU, ZHENG, YAN
Publication of US20230228667A1 publication Critical patent/US20230228667A1/en
Application granted granted Critical
Publication of US11796443B2 publication Critical patent/US11796443B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Definitions

  • the present invention belongs to the technical field of cell sorting. More specifically, the present invention relates to a method for isolating placental trophoblast cells from cervical exfoliated cells of a pregnant woman.
  • the three-level (pre-pregnancy, antenatal and newborn) prevention and control system is one of the important means to reduce birth defects and to improve population quality in China, among which prenatal screening and diagnosis is the most complex and most difficult part.
  • amniocentesis or cordocentesis various disadvantages exist in clinically used prenatal diagnostic technologies such as, amniocentesis or cordocentesis, and non-invasive prenatal screening methods like fetal free nucleic acid sequencing.
  • the amniocentesis and cordocentesis have high risks of infection during sampling and abortion, long analysis period, limited detection items and range.
  • the diagnosis time is limited within the middle and advanced stages of pregnancy, pregnant women have low acceptability of these two technologies, and the clinical treatment is difficult.
  • the fetal free nucleic acid sequencing technology has extremely limited test range, and can only detect 3-5 designated chromosome aneuploid, and it's hard to avoid false positive and false negative cases using this method.
  • the technology has insufficient capacity in the detection of common mutations and the individual differences exist in the content of fetal free nucleic acids in maternal blood.
  • the applicant discloses a method for isolating trophoblast cells in patent application CN111304153A.
  • this method by determining a specific antigen expressed on the surface of trophoblast cells and by using immunomagnetic beads carrying the corresponding specific antibody, the placental trophoblast cells are isolated from a cell suspension of a placental trophoblast sample and purified.
  • the technology Compared with the conventional amniocentesis and chorionic villus sampling, the technology has the advantages of non-invasive, earlier sampling time, low risk of infection and abortion, and similar reliability of test results.
  • the technology still has space for the improvement of the applicable antibodies whose disclosed combinations are still limited, accuracy and specificity.
  • the applicant team has carried out continuous research and development to the project.
  • the objective of the present invention is to provide a method for isolating placental trophoblast cells from cervical exfoliated cells of a pregnant woman based on flow cytometry separation or microfluidics.
  • the present invention not only overcomes the problems and defects of conventional methods, but also can achieve the synchronous labeling of a plurality of antigens as well as identification and sorting of characteristic fluorescence signals simultaneously; and the method has greatly improved accuracy and specificity superior to the previous immunomagnetic beads separation solution.
  • the method has advantages in the improvement of both cell quantity and quality. The number of cells obtained is larger than that of conventional methods, with good specificity and sensitivity.
  • the microfluidic sorting chip in the step (3) has a structure: including a substrate and a cover plate fitted therewith; the chip is made via the injection molding technology from base material, including but not limited to acrylic.
  • One side of the substrate is provided with a main runner, a side runner A and a side runner B, and the two side runners are close to left and right end portions of the main runner, correspondingly.
  • Another side of the substrate is provided with an inlet C, an inlet S, an outlet N and an outlet T; all the two inlets and the two outlets penetrate the substrate to communicate with the runners on the other side; and a position of the inlet C corresponds to the left end portion of the main runner; a position of the inlet S corresponds to the end portion of the side runner A; a position of the outlet N corresponds to the right end portion of the main runner; and a position of the outlet T corresponds to the end portion of the side runner B.
  • a deflection electrode device is further disposed in the main runner and at a convergence site of the outlet N and the outlet T.
  • the main runner, the side runner A and the side runner B have a width not greater than 1000 ⁇ m and a depth not greater than 500 ⁇ m.
  • the main runner, the side runner A and the side runner B have a width of 500-1000 ⁇ m.
  • the main runner, the side runner A and the side runner B have a width of 1000 ⁇ m.
  • the inlet C is used for feeding the mixed cell sample to be sorted; the inlet S is used for feeding a buffer solution; the outlet T is used for collecting target cells, and the outlet N is used for collecting non-target cells.
  • the mixed sample containing target cells flows into the main runner of the chip from the inlet C, and the buffer solution flows into the side runner from the inlet S; the two are mixed at the intersection of the runners and then continuously flow along the same direction of the main runner.
  • the runner into which the cells are about to flow is controlled by selected by controlling the on/off of the electrode; the target cells are sorted to reach the outlet T, while the non-target cells continue to flow along the main runner to reach the outlet N, thus completing the sorting.
  • a primary antibody in the step (2) is incubated in the following conditions: reacting for 30-90 min at 4° C., preferably, reacting for 60 min at 4° C.; and a second antibody-fluorescent labeling complex is incubated in the following conditions: reacting for 20 min at 2° C.-8° C.
  • the step (2) specifically includes: successively and specifically binding the primary antibody and the second antibody-fluorescent labeling complex to a target antigen step by step via incubation, wherein a washing and centrifugal separation technology is used to avoid cross contamination during the binding process.
  • the step (3) specifically includes: feeding the incubated cell resuspension into the inlet C of the microfluidic sorting chip, feeding the buffer solution into the inlet S, then placing the microfluidic sorting chip in a cell sorter to carry out the sorting program, and collecting specimens at the outlet T at the end of the sorting program to obtain sorted trophoblast cells.
  • a liquid-phase cell sorting system in the step (3) is 0.2%-0.4% Triton-X-100, preferably, 0.3% Triton-X-100. More preferably, PBS is used for preparation.
  • the sorting conditions of the flow cytometer in the step (3) are as follows: a sample loading rate is adjusted within 1000-2000 events/s, and a collecting rate is 5.0.
  • an optimal system of the cell suspension in the step (1) is 1 ⁇ PBS containing 0.2%-0.4% FBS, preferably, 1 ⁇ PBS containing 0.3% FBS.
  • an application of the method in the construction of products for human STR authentication, human chromosome ploidy detection, thalassemia gene testing, epicophosis gene testing, whole exome sequencing, chromosome microdeletion/duplicate detection (a high-throughput sequencing method), or chromosome structure variation detection (a high-density chip method) shall also fall within the protection scope of the present invention.
  • the method for isolating placental trophoblast cells based on flow cytometry separation or microfluidics has the advantages of non-invasively obtaining specimens, earlier sampling time, low risk of infection and abortion, and the test result has higher reliability and broader coverage area.
  • Whole genome nucleic acid samples of fetus can be obtained by such kind of specimen, which makes the detection and analysis of all the genetic diseases possible, and basically achieves the coverage of genetic diseases detection (chromosome ploidy, chromosome structure variation CNV, mitochondria, microdeletion/duplicate, single-gene mutation, SNP/STR genetic characteristics detection, and the like).
  • the method of the present invention can obtain considerable cells (thousands of cells, the designed minimum quality control standard is greater than 2000 positive cells), and can achieve the specimen detection by the conventional molecular assay technique without special operations. Moreover, the method of the present invention has no strict requirement for technicians and laboratory equipment, which reduces the technical thresholds and use costs and can be carried out in more medical institutions, capable of being popularized in wide range.
  • the method provided by the present invention is a multi-labeling screening solution, which can achieve the synchronous labeling of a more plurality of antigens as well as identification and sorting of characteristic fluorescence signals simultaneously, and the accuracy has been greatly improved.
  • the method of the present invention can both have the advantages of cell quantity and quality.
  • the cells obtained are not only numerous, but also have minor injury, and the cells obtained have good quality, good detection specificity and sensitivity.
  • FIG. 1 is a schematic diagram showing a substrate structure of a microfluidic sorting chip; figures ( a ) and ( b ) respectively represent the two sides of the substrate;
  • FIG. 2 shows a mono-fluorescence labeled positive cell population selected in flow cytometry sorting
  • FIG. 3 shows a bifluorescence labeled positive cell population selected in flow cytometry sorting
  • FIG. 4 is an FAM-labeled channel 1 ; “ 822 ⁇ ” represents the rest specimens after sorting; “ 822 +” represents sorted specimens; “ 822 ” represents specimens before sorting;
  • FIG. 5 is an HEX-labeled channel 2 ;
  • FIG. 6 is a TAMRA-labeled channel 3 ;
  • FIG. 7 is a ROX-labeled channel 4 ;
  • FIG. 8 is a schematic diagram showing a test result of Y-STR of the Y-chromosome containing specimen in the sorted plasmoditrophoblast cells;
  • FIG. 9 is a test result of epicophosis genes of the sorted specimen.
  • FIG. 10 is a test result of thalassemia genes of the sorted specimen
  • FIG. 11 shows a family genogram carrying detected family pathogenic mutations
  • FIG. 12 is a schematic diagram showing whole chromosomes
  • FIG. 13 is a schematic diagram showing abnormal chromosomes
  • FIG. 14 is a picture showing positive cells sorted by the method of the present invention.
  • FIG. 15 is a picture showing comparison of positive cells and negative cells before and after sorting using the method of the present invention.
  • FIG. 16 is a picture showing positive cells sorted by the control method of immunomagnetic beads.
  • the present invention will be further described in combination with the detailed embodiments of the description, and the embodiments are not used to limit the present invention in any form.
  • the reagent, method and equipment used in the present invention are conventional reagent, method and equipment in the art.
  • FIG. 1 The schematic diagram of the microfluidic sorting chip for isolating trophoblast cells from cervical exfoliated cells of a pregnant woman is shown in FIG. 1 .
  • the structure of the microfluidic sorting chip is designed and described below: the chip is prepared by including but not limited to acrylic as a base material; a pipe shape of FIG. 1 was formed on one side of the base material via the injection molding technology, with the pipe width not greater than 1000 ⁇ m, and depth not greater than 500 ⁇ m, and another side of the base material is used for fitting to form a complete chip.
  • the microfluidic sorting chip includes a substrate and a cover plate fitted therewith.
  • one side of the substrate is provided with a main runner, a side runner A and a side runner B, and the two side runners are respectively close to left and right end portions of the main runner; and all the runners have a width of 1000 ⁇ m.
  • Another side of the substrate is provided with an inlet C (a liquid inlet for cell samples), an inlet S (a liquid inlet for buffer solution), an outlet N (a liquid storage hole for non-target cells) and an outlet T (a liquid storage hole for target cells); all the two inlets and the two outlets penetrate the substrate to communicate with the runners; and a position of the inlet C corresponds to the left end portion of the main runner; a position of the inlet S corresponds to the end portion of the side runner A; a position of the outlet N corresponds to the right end portion of the main runner; and a position of the outlet T corresponds to the end portion of the side runner B.
  • inlet C a liquid inlet for cell samples
  • an inlet S a liquid inlet for buffer solution
  • an outlet N a liquid storage hole for non-target cells
  • an outlet T a liquid storage hole for target cells
  • the inlet C is used for feeding the mixed cell samples to be sorted; the inlet S is used for feeding the buffer solution; the outlet T is used for collecting the target cells, and the outlet N is used for collecting the non-target cells.
  • the main runner is further provided with a deflection electrode device for cell sorting; the deflection electrode device is specifically located at the intersection of the outlet N and the outlet T; the on/off of the electrode may be controlled according to the presence of a flow cell signal.
  • Negatively-charged cells are subjected to deflection in the electromagnetic field formed by electrodes to flow into a designated pipe leading to the outlet N or the outlet T.
  • the mixed sample containing target cells flows into the main runner of the chip from the inlet C, and the buffer solution flows into the side runner from the inlet S; the two are mixed at the intersection of the runners and then continuously flow along the same direction of the main runner.
  • the runner into which the cells flow are about to flow is selected by controlling the on/off of the electrode; the target cells are sorted to reach the outlet T, while the non-target cells continue to reach the outlet N along with the main runner, thus completing the sorting.
  • the chip is immediately discarded, and a new chip needs to be exchanged before each sorting to ensure a clean, controllable and cross contamination-free sorting environment.
  • FIG. 2 shows a sorting result of mono-fluorescence labeling
  • FIG. 3 shows a sorting result of bifluorescence labeling.
  • PCR reaction procedure PCR reaction was performed for 10 min at 50° C. and for 4 min at 96° C. (5 sec at 94° C. and 1 min+10 sec at 60° C.) ⁇ 27 cycles, for 30 min at 60° C., and preserved at 15° C.
  • the specimen of Y chromosome detected in STR was subjected to Y-STR detection with a Microread 40Y kit. Results are shown in FIG. 8 , and the results show that there exists male DNA in the specimen.
  • Example 2 for Medical Device of the People's Republic of China: 20153401698) according to the method of Example 2; specifically, 9 mutation sites (mtDNA1494, mtDNA1555, SLC26A4-IVS7(-2), SLC26A4-2168, GJB2-35, GJB2-176, GJB2-235, GJB2-299 and GJB3-538) of the epicophosis-related genes (GJB2, GJB3, SLC26A4 and mtDNA) were subjected to testing.
  • 9 mutation sites mtDNA1494, mtDNA1555, SLC26A4-IVS7(-2), SLC26A4-2168, GJB2-35, GJB2-176, GJB2-235, GJB2-299 and GJB3-538
  • the DNA extraction method of the cervical exfoliated cells of a pregnant woman in Example 4 was used, and then a commercial kit (epicophosis-susceptible gene kit (PCR+flow-through hybridization), Chaozhou Hybribio Biochemistry Co., Ltd., Registration Certificate No. for Medical Device of the People's Republic of China: 20153401698) was used for subsequent testing. Specific operations are specifically shown in the instructions. Raw data are shown in FIG. 9 ; and result analysis are shown in Table 3.
  • Cervical exfoliated cells of a pregnant woman were subjected to epicophosis-susceptible gene testing with a commercial kit ( ⁇ - and ⁇ -thalassemia gene kit (PCR+membrane hybridization method), Chaozhou Hybribio Biochemistry Co., Ltd., SFDA Certified No.: 3400399, 2012) according to the method of Example 2; specifically, 3 common ⁇ -thalassemia deletion types (— SEA ,- ⁇ 3.7 , - ⁇ 4.2 ), 2 ⁇ -thalassemia mutant types (CS and QS) and 11 ⁇ -thalassemia mutant types (CD14-15, CD17, CD27-28, CD41-42, CD43, CD71-72, -28, -29, IVS-I-1, IVS-II-654 and ⁇ EN) were subjected to testing.
  • ⁇ - and ⁇ -thalassemia gene kit PCR+membrane hybridization method
  • CS and QS 2 ⁇ -thalassemia mutant types
  • the DNA extraction method of the cervical exfoliated cells of a pregnant woman in Example 4 was used, and then a commercial kit ( ⁇ - and ⁇ -thalassemia gene kit (PCR+membrane hybridization method), Chaozhou Hybribio Biochemistry Co., Ltd., SFDA Certified No.: 3400399, 2012) was used for subsequent testing. Specific operations are specifically shown in the instructions. Raw data are shown in FIG. 10 ; and result analysis is shown in Table 4.
  • the genome DNA was processed into 300 bp fragments with a transposase Tn5 to construct a DNA library; adapters P5, P7, index1, 2 were added at both terminals; a proper length of DNA fragments was chosen, amplified and purified, then hybridized with the exon probe library with biotin; strong binding force of the biotin to streptavidin was used to bind streptavidin-carrying magnetic beads with the probe which had been bound to the target library; the magnetic beads were adsorbed and supernatant was removed, and DNA on the magnetic beads was eluted, and the library was subjected to PCR amplification, and quality evaluation; and sequencing on a machine was performed.
  • the schematic diagram of whole chromosomes is shown in FIG. 12 and the schematic diagram of abnormal chromosomes is shown in FIG. 13 .
  • the horizontal axis represents the schematic diagram of a chromosome zone, and longitudinal axis shows a signal ratio of the sample to the standard sample (represented by a log 2 ratio).
  • the chromosome CNV has a significant difference, it is represented by different colors.
  • the region (Gain) where chromosome is amplified is represented by blue
  • the region (Loss) where chromosome is deleted is represented by red.
  • the length and value of the black line respectively represent the mean size and signal of each Segment.
  • One abnormity is detected in the sample, namely, 22q11.21 deletion; the start-end positions [UCSC hg19] of the abnormal fragment are arr22q11.21 (19006943_21461068) ⁇ 1 with a size of 2.454 Mb.
  • Related disease area is Pathogenic (pathogenicity, ACMG classification); and such abnormal fragment covers 106 ISCA genes, such as TBX1, CRKL, GP1BB, SLC25A1, DGCR10, TSSK1A, GSC2 and CLTCL1.
  • the regional anomaly is located at 22q11.2 recurrent (DGS/VCFS) region (includes TBX1).
  • the deletion of 22q11.2 proximal (A-D) region is related to the DiGeorge/Velocardioffacial (DGS/VCFS) syndrome which is generally clinically featured by congenital heart disease, heart abnormity, characteristic facial features, DD/ID, behavior disorders, immune deficiency and hypocalcemia (PMID 25217958).
  • the regional anomaly is located at 22q11.2 recurrent region (central, B/C-D) (includes CRKL).
  • the clinical phenotypes possibly caused by the region deletion includes: deformed facial features, growth restriction/short stature, central nervous system abnormity/attack, developmental retardation, dysgnosia, skeletal anomalies, cardiovascular defects, urogenital system anomalies, immune deficiency/repeated infection (PMID 25123976).
  • the results indicate that the sorted cell specimen can be effectively subjected to chromosome structure variation detection and corresponding mutations can be detected.
  • the method of the present invention was the same as that in Example 2.
  • the process for sorting trophoblast cells by the immunomagnetic beads includes the following steps:
  • FIG. 14 is a picture showing positive cells sorted by the method of the present invention
  • FIG. 15 is a picture showing comparison of positive cells and negative cells before and after being sorted by the method of the present invention
  • FIG. 16 is a picture showing positive cells sorted by the immunomagnetic beads. It can be obviously seen from the comparison that there is an obvious difference in the order of magnitudes of the cell population after being sorted by the two methods; the method of the present invention is significantly superior to the immunomagnetic beads.
  • Statistics show that the number of positive cells sorted by the method of the present invention may be up to about 3000-13,000.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US18/009,740 2021-05-20 2022-03-16 Method for isolating placental trophoblast cells from cervical exfoliated cells of pregnant woman Active US11796443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110549947.8A CN112980779B (zh) 2021-05-20 2021-05-20 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法
CN202110549947.8 2021-05-20
PCT/CN2022/081234 WO2022242285A1 (zh) 2021-05-20 2022-03-16 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法

Publications (2)

Publication Number Publication Date
US20230228667A1 US20230228667A1 (en) 2023-07-20
US11796443B2 true US11796443B2 (en) 2023-10-24

Family

ID=76337075

Family Applications (1)

Application Number Title Priority Date Filing Date
US18/009,740 Active US11796443B2 (en) 2021-05-20 2022-03-16 Method for isolating placental trophoblast cells from cervical exfoliated cells of pregnant woman

Country Status (8)

Country Link
US (1) US11796443B2 (sl)
EP (1) EP4144834A4 (sl)
JP (1) JP7368642B2 (sl)
KR (1) KR102626620B1 (sl)
CN (1) CN112980779B (sl)
AU (1) AU2022277079A1 (sl)
BR (1) BR112022024743B1 (sl)
WO (1) WO2022242285A1 (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112980779B (zh) * 2021-05-20 2021-08-24 广州凯普医药科技有限公司 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432441A (zh) 2006-03-23 2009-05-13 生物概念股份有限公司 分离胎儿滋养层
CN101726585A (zh) 2009-11-30 2010-06-09 宁波普赛微流科技有限公司 一种基于微流控芯片的流式细胞仪
CN103983794A (zh) 2013-02-12 2014-08-13 李木 一种微流控芯片及一种微流控方法
US20160090631A1 (en) 2013-06-11 2016-03-31 James R. STELLING Method for detection of fetal abnormalities
CN108535228A (zh) 2018-04-03 2018-09-14 厦门大学 一种从孕妇外周血中分离游离胎儿细胞的方法
CN109312332A (zh) 2016-04-06 2019-02-05 韦恩州立大学 自子宫颈内管获取的绒毛外滋养层细胞的胎儿dna的分离与分析
CN111304153A (zh) 2019-12-17 2020-06-19 广东凯普生物科技股份有限公司 一种分离滋养层细胞的方法
CN111440696A (zh) 2020-02-26 2020-07-24 厦门大学 胎儿细胞捕获模块、用于胎儿细胞捕获的微流控芯片，及它们的使用方法
CN112980779A (zh) 2021-05-20 2021-06-18 广州凯普医药科技有限公司 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68928535T2 (de) * 1988-12-06 1998-04-16 Flinders Technologies Pty Ltd Isolierung von fetalen zellen aus mütterlichem blut zur ausführung von pränataler diagnostik
EP0662152A1 (en) * 1992-07-17 1995-07-12 Aprogenex, Inc. Enriching and identyfying fetal cells in maternal blood for in situ hybridization
US5714325A (en) * 1993-09-24 1998-02-03 New England Medical Center Hospitals Prenatal diagnosis by isolation of fetal granulocytes from maternal blood
JPH11503320A (ja) * 1995-04-07 1999-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ−ｇ検出用抗体
US20020045196A1 (en) * 2000-05-12 2002-04-18 Walt Mahoney Methods of isolating trophoblast cells from maternal blood
AUPR749901A0 (en) * 2001-09-06 2001-09-27 Monash University Method of identifying chromosomal abnormalities and prenatal diagnosis
US20050181429A1 (en) * 2003-04-03 2005-08-18 Monaliza Medical Ltd. Non-invasive prenatal genetic diagnosis using transcervical cells
US20040197832A1 (en) * 2003-04-03 2004-10-07 Mor Research Applications Ltd. Non-invasive prenatal genetic diagnosis using transcervical cells
WO2005047532A1 (en) * 2003-11-17 2005-05-26 Gribbles Molecular Science Pty Ltd Improved method of performing genetic analyses on reproductive tract cell samples
DE102007019017A1 (de) * 2007-04-19 2009-01-22 Ldt Laser Display Technology Gmbh Verfahren und Vorrichtung zum Projizieren eines Bildes auf eine Projektionsfläche
ITTO20070307A1 (it) * 2007-05-04 2008-11-05 Silicon Biosystems Spa Metodo e dispositivo per la diagnosi prenatale non-invasiva
EP2419507A1 (en) * 2009-04-14 2012-02-22 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
EP2421955A4 (en) * 2009-04-21 2012-10-10 Genetic Technologies Ltd METHODS OF OBTAINING F TAL GENETIC MATERIAL
ES2666594T3 (es) * 2012-05-24 2018-05-07 Rarecells Procedimiento para diagnosticar un cáncer invasivo
TR201908019T4 (tr) * 2012-10-19 2019-06-21 Univ Wayne State Doğum öncesi teşhis için servikal mukusta fetal trofoblast hücrelerinin tanımlanması ve analizi.
CN107312747A (zh) * 2016-12-20 2017-11-03 华东医药（杭州）基因科技有限公司 一种免疫磁珠法分离胎盘滋养层细胞的方法
CN108265051B (zh) * 2016-12-30 2020-08-25 张婧 用于从母体捕获和分离胎儿细胞的无创方法和试剂盒
WO2019153032A1 (en) * 2018-02-07 2019-08-15 University Of South Australia Pre-natal cell isolation
TWI668423B (zh) * 2018-10-02 2019-08-11 吳宏偉 細胞分選方法及系統
CN110117571B (zh) * 2019-05-08 2023-01-31 南方医科大学南方医院 无创获取胎儿稀有细胞的试剂盒及其方法
KR20220047929A (ko) * 2019-06-07 2022-04-19 아크에디 바이오테크 에이피에스 Facs를 사용하는 태아 세포의 분리
KR20230114327A (ko) * 2019-07-15 2023-08-01 메나리니 바이오마커스 싱가포르 피티이 리미티드 태아 세포의 단리, 검출 및 분석을 위한 조성물 및방법

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432441A (zh) 2006-03-23 2009-05-13 生物概念股份有限公司 分离胎儿滋养层
CN101726585A (zh) 2009-11-30 2010-06-09 宁波普赛微流科技有限公司 一种基于微流控芯片的流式细胞仪
CN103983794A (zh) 2013-02-12 2014-08-13 李木 一种微流控芯片及一种微流控方法
US20160090631A1 (en) 2013-06-11 2016-03-31 James R. STELLING Method for detection of fetal abnormalities
CN109312332A (zh) 2016-04-06 2019-02-05 韦恩州立大学 自子宫颈内管获取的绒毛外滋养层细胞的胎儿dna的分离与分析
CN108535228A (zh) 2018-04-03 2018-09-14 厦门大学 一种从孕妇外周血中分离游离胎儿细胞的方法
CN111304153A (zh) 2019-12-17 2020-06-19 广东凯普生物科技股份有限公司 一种分离滋养层细胞的方法
CN111440696A (zh) 2020-02-26 2020-07-24 厦门大学 胎儿细胞捕获模块、用于胎儿细胞捕获的微流控芯片，及它们的使用方法
CN112980779A (zh) 2021-05-20 2021-06-18 广州凯普医药科技有限公司 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"International Search Report (Form PCT/ISA/210) of PCT/CN2022/081234," dated Jun. 20, 2022, with English translation thereof, pp. 1-6.
Fu Xiang-Long et al., "Progress on Isolation and Culture of Placental Trophoblast Cells in Vitro", Progress in Veterinary Medicine, submit with English abstract, Dec. 2012, pp. 97-100.
Li Dan et al., "Advances in the application of transcervical trophoblast cells in prenatal diagnosis", International Journal of Laboratory Medicine, submit with English abstract, Mar. 2019, pp. 597-600.

Also Published As

Publication number Publication date
JP2023527246A (ja) 2023-06-27
KR102626620B1 (ko) 2024-01-17
EP4144834A4 (en) 2023-09-27
CN112980779B (zh) 2021-08-24
CN112980779A (zh) 2021-06-18
BR112022024743A2 (sl) 2023-06-27
US20230228667A1 (en) 2023-07-20
JP7368642B2 (ja) 2023-10-24
BR112022024743B1 (pt) 2024-03-05
WO2022242285A1 (zh) 2022-11-24
AU2022277079A1 (en) 2023-01-19
EP4144834A1 (en) 2023-03-08
KR20230004915A (ko) 2023-01-06

Similar Documents

Publication Publication Date Title
Bianchi Fetal cells in the maternal circulation: feasibility for prenatal diagnosis.
JP6310540B2 (ja) 母体血液中の胎児細胞の濃縮及び同定及びこれに使用するリガンド
Vona et al. Enrichment, immunomorphological, and genetic characterization of fetal cells circulating in maternal blood
Hahn* et al. Current applications of single-cell PCR
US20050123914A1 (en) Method of isolating cells and uses thereof
US20230092810A1 (en) Fetal cell capture module and microfluidic chip for fetal cell capture and methods for using the same
US20050181429A1 (en) Non-invasive prenatal genetic diagnosis using transcervical cells
US20030232377A1 (en) Early noninvasive prenatal test for aneuploidies and heritable conditions
KR20050123139A (ko) 경자궁경부 세포를 이용한 비침습성 산전 유전자 진단
EP2152905B1 (en) Methods and kits for detecting fetal cells in the maternal blood
NZ542698A (en) Obtaining foetal calls suitable for enrichment and subsequent analysis from a cervical sample such as a Pap smear
US11796443B2 (en) Method for isolating placental trophoblast cells from cervical exfoliated cells of pregnant woman
CN103797368A (zh) 胎儿有核红细胞的检测
Sekizawa et al. Fetal cell recycling: diagnosis of gender and RhD genotype in the same fetal cell retrieved from maternal blood
CN106544411A (zh) 一种利用标识蛋白分析鉴定哺乳动物y精子分型的方法
WO2005047532A1 (en) Improved method of performing genetic analyses on reproductive tract cell samples
Holzgreve et al. Fetal cells in cervical mucus and maternal blood
Goldberg Fetal cells in maternal circulation: progress in analysis of a rare event.
CN111781360A (zh) 游离细胞捕获探针及其相关产品和用途
RU2808260C1 (ru) Способ отделения клеток плацентарного трофобласта от отслоившихся клеток шейки матки беременных женщин
US20060105353A1 (en) Non-invasive prenatal fetal cell diagnostic method
Bianchi Progress in the genetic analysis of fetal cells circulating in maternal blood
US20160090631A1 (en) Method for detection of fetal abnormalities
Chiu et al. Non-invasive prenatal diagnosis: on the horizon?
van Dijk et al. Tricky TRIC: A replication study using trophoblast retrieval and isolation from the cervix to study genetic birth defects

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: GUANGDONG HYBRIBIO BIOTECH CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHENG, YAN;MA, JIAYAN;FENG, XIAOWEI;AND OTHERS;REEL/FRAME:062097/0172

Effective date: 20221205

Owner name: GUANGZHOU HYBRIBIO MEDICINE TECHNOLOGY LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHENG, YAN;MA, JIAYAN;FENG, XIAOWEI;AND OTHERS;REEL/FRAME:062097/0172

Effective date: 20221205

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: AWAITING TC RESP, ISSUE FEE PAYMENT VERIFIED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE